

Specimen Details

Date collected: 11/17/2017 0855 Local
Date received: 11/17/2017
Date entered: 11/17/2017
Date reported: 11/22/2017 1410 ET

General Comments & Additional Information

Total Volume: Not Provided

Fasting: Yes

Ordered Items

NMR LipoProfile; Vitamin A and E; CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel; Iron and TIBC; Heavy Metals Profile I, Blood; Lp-PLA2 Activity; Hemoglobin A1c; Cortisol; IGF-1; Zinc, RBC; Reverse T3, Serum; Vitamin D, 25-Hydroxy; C-Reactive Protein, Cardiac; Thyroid Cascade Profile; Homocyst(e)ine, Plasma; Uric Acid, Serum; GGT; Insulin; Ferritin, Serum; Triiodothyronine, Free, Serum; Apolipoprotein A-1; Fatty Acids, Free (Nonester); Apolipoprotein B; Venipuncture

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
NMR LipoProfile					
LDL Particle Number					01
LDL-P	1059	High	nmol/L	<1000	01
		Low		< 1000	
		Moderate		1000 - 1299	
		Borderline-High		1300 - 1599	
		High		1600 - 2000	
		Very High		> 2000	
Lipids					01
LDL-C	87		mg/dL	0 - 99	
			Optimal	< 100	
			Above optimal	100 - 129	
			Borderline	130 - 159	
			High	160 - 189	
			Very high	> 189	
Comment:					01
	LDL-C is inaccurate if patient is non-fasting.				
HDL-C	44		mg/dL	>39	01
Triglycerides	125		mg/dL	0 - 149	01
Cholesterol, Total	156		mg/dL	100 - 199	01
LDL and HDL Particles					01
HDL-P (Total)	30.1	Low	umol/L	>=30.5	01
Small LDL-P	330		nmol/L	<=527	01
LDL Size	20.6		nm	>20.5	01

**** INTERPRETATIVE INFORMATION****

PARTICLE CONCENTRATION AND SIZE

<--Lower CVD Risk Higher CVD Risk-->

LDL AND HDL PARTICLES	Percentile	in Reference Population
HDL-P (total)	High	75th 50th 25th Low
	>34.9	34.9 30.5 26.7 <26.7
Small LDL-P	Low	25th 50th 75th High

Patient ID:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
LDL Size	<-Large (Pattern A)-> 23.0	117	527	839 >839 <-Small (Pattern B)-> 20.5 19.0	

Comment:

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account. These assays were developed and their performance characteristics determined by LipoScience. These assays have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values have not been fully established.

01

Insulin Resistance Score

LP-IR Score 67 High <=45

01

INSULIN RESISTANCE MARKER

<--Insulin Sensitive Insulin Resistant-->
Percentile in Reference Population

Insulin Resistance Score

LP-IR Score	Low	25th	50th	75th	High
	<27	27	45	63	>63

01

Comment:

LP-IR Score is inaccurate if patient is non-fasting. The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. The LP-IR score listed above has not been cleared by the US Food and Drug Administration.

01

Vitamin A and E

Vitamin A, Serum	50	ug/dL	24 - 85	01
Vitamin E (Alpha Tocopherol)	16.3	mg/L	5.3 - 17.5	01

CBC With Differential/Platelet

WBC	4.4	x10E3/uL	3.4 - 10.8	02
RBC	5.36	x10E6/uL	4.14 - 5.80	02
Hemoglobin	16.2	g/dL	12.6 - 17.7	02

****Effective December 4, 2017 the reference interval**
for Hemoglobin MALES only will be changing to:
Males 13-15 years: 12.6 - 17.7
Males >15 years: 13.0 - 17.7**

Hematocrit	46.3	%	37.5 - 51.0	02
MCV	86	fL	79 - 97	02
MCH	30.2	pg	26.6 - 33.0	02
MCHC	35.0	g/dL	31.5 - 35.7	02
RDW	13.7	%	12.3 - 15.4	02
Platelets	278	x10E3/uL	150 - 379	02
Neutrophils	47	%	Not Estab.	02
Lymphs	40	%	Not Estab.	02
Monocytes	9	%	Not Estab.	02

Patient ID:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Eos	3		%	Not Estab.	02
Basos	1		%	Not Estab.	02
Neutrophils (Absolute)	2.1		x10E3/uL	1.4 - 7.0	02
Lymphs (Absolute)	1.8		x10E3/uL	0.7 - 3.1	02
Monocytes (Absolute)	0.4		x10E3/uL	0.1 - 0.9	02
Eos (Absolute)	0.1		x10E3/uL	0.0 - 0.4	02
Baso (Absolute)	0.0		x10E3/uL	0.0 - 0.2	02
Immature Granulocytes	0		%	Not Estab.	02
Immature Grans (Abs)	0.0		x10E3/uL	0.0 - 0.1	02
Comp. Metabolic Panel (14)					
Glucose, Serum	73		mg/dL	65 - 99	02
BUN	13		mg/dL	6 - 24	02
Creatinine, Serum	0.82		mg/dL	0.76 - 1.27	02
eGFR If NonAfricn Am	111		mL/min/1.73	>59	
eGFR If Africn Am	128		mL/min/1.73	>59	
BUN/Creatinine Ratio	16			9 - 20	
Sodium, Serum	140		mmol/L	134 - 144	02
Potassium, Serum	4.4		mmol/L	3.5 - 5.2	02
Chloride, Serum	97		mmol/L	96 - 106	02
Carbon Dioxide, Total	24		mmol/L	18 - 29	02
Calcium, Serum	9.3		mg/dL	8.7 - 10.2	02
Protein, Total, Serum	6.9		g/dL	6.0 - 8.5	02
Albumin, Serum	4.6		g/dL	3.5 - 5.5	02
Globulin, Total	2.3		g/dL	1.5 - 4.5	
A/G Ratio	2.0			1.2 - 2.2	
Bilirubin, Total	0.8		mg/dL	0.0 - 1.2	02
Alkaline Phosphatase, S	54		IU/L	39 - 117	02
AST (SGOT)	24		IU/L	0 - 40	02
ALT (SGPT)	24		IU/L	0 - 44	02
Lipid Panel					
Cholesterol, Total	161		mg/dL	100 - 199	02
Triglycerides	120		mg/dL	0 - 149	02
HDL Cholesterol	43		mg/dL	>39	02
VLDL Cholesterol Calc	24		mg/dL	5 - 40	
LDL Cholesterol Calc	94		mg/dL	0 - 99	
Iron and TIBC					
Iron Bind.Cap. (TIBC)	324		ug/dL	250 - 450	
UIBC	203		ug/dL	111 - 343	02
Iron, Serum	121		ug/dL	38 - 169	02
Iron Saturation	37		%	15 - 55	

Patient ID:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Heavy Metals Profile I, Blood					
Lead, Blood	None Detected		ug/dL	0 - 19	01
			Environmental Exposure:		
			WHO Recommendation	<20	
			Occupational Exposure:		
			OSHA Lead Std	40	
			BEI	30	
			Detection Limit =	1	
Arsenic, Blood	6		ug/L	2 - 23	01
			Detection Limit =	1	
Mercury, Blood	None Detected		ug/L	0.0 - 14.9	01
			Environmental Exposure:	<15.0	
			Occupational Exposure:		
			BEI - Inorganic Mercury:	15.0	
			Detection Limit =	1.0	
Lp-PLA2 Activity					
Lp-PLA2 Activity	60		nmol/min/mL	<75	03
	Relative Risk: LOW				
	Based on the documented clinical utility of Lp-PLA2 Activity to assess risk of CHD (1), the following cut-off has been defined for Lp-PLA2 Activity: A cut-off of ≥ 75 nmol/min/mL defines a population with increased relative risk of developing CHD. (Reference: 1-The Lp-PLA2 Studies Collaboration. Lancet. 2010; 375: 1536-1544).				
	This test is performed by a Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS) method. This test was developed and its performance characteristics determined by the Cleveland HeartLab, Inc. It has not been cleared or approved by the U.S. FDA. The Cleveland HeartLab is regulated under Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.				
	Effective January 8, 2018, Lp-PLA2 Activity will be made non-orderable. LabCorp will offer order code 123283 Lp-PLA2 Activity. For further information, please contact your local LabCorp Representative.				
PDF Image	.				03
Hemoglobin A1c					
Hemoglobin A1c	4.9		%	4.8 - 5.6	02
Please Note:					02
	Pre-diabetes: 5.7 - 6.4				
	Diabetes: >6.4				
	Glycemic control for adults with diabetes: <7.0				
Cortisol	7.9		ug/dL		02
			Cortisol AM	6.2 - 19.4	
			Cortisol PM	2.3 - 11.9	

Patient ID:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
IGF-1					
Insulin-Like Growth Factor I	153		ng/mL	83 - 233	01
Zinc, RBC	1384		ug/dL	878 - 1660	01
Reverse T3, Serum	27.4	High	ng/dL	9.2 - 24.1	01
Vitamin D, 25-Hydroxy	49.4		ng/mL	30.0 - 100.0	02
Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).					
1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.					
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.					
C-Reactive Protein, Cardiac	1.99		mg/L	0.00 - 3.00	02
Relative Risk for Future Cardiovascular Event					
Low <1.00					
Average 1.00 - 3.00					
High >3.00					
Thyroid Cascade Profile					
TSH	3.070		uIU/mL	0.450 - 4.500	02
Homocyst(e)ine, Plasma	<3.0		umol/L	0.0 - 15.0	02
Uric Acid, Serum					
Uric Acid, Serum	6.6		mg/dL	3.7 - 8.6	02
Please Note:					02
Therapeutic target for gout patients: <6.0					
GGT	13		IU/L	0 - 65	02
Insulin	5.6		uIU/mL	2.6 - 24.9	02
Ferritin, Serum	333		ng/mL	30 - 400	02
Triiodothyronine, Free, Serum	2.7		pg/mL	2.0 - 4.4	02
Apolipoprotein A-1	138		mg/dL	101 - 178	01
Fatty Acids, Free (Nonester)	0.8	High	mEq/L	0.1 - 0.6	01

Patient ID:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Apolipoprotein B	83		mg/dL	52 - 135	01

01	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: William F Hancock, MD
02	PDLCA	LabCorp Phoenix 5005 S 40th Street Ste 1200, Phoenix, AZ 85040-2969	Dir: Brian Poirier, MD
03	CLHRT	Cleveland Heartlab Inc 6701 Carnegie Avenue Ste 500, Cleveland, OH 44103-4623	Dir: Deborah Sun, PhD

For inquiries, the physician may contact **Branch: 888-522-2677 Lab: 800-762-4344**

COMPLETE REPORT

PATIENT INFORMATION		SPECIMEN INFORMATION		PRACTITIONER INFORMATION	
Age		Order ID		Name	LABCORP LABCORP
Patient ID	Gender Male	Collection Date/Time 11/17/2017, 08:55 AM		Client ID	LABCORP PHOENIX
Fasting Status Fasting	DOB	Received Date/Time 11/21/2017, 2:17 PM		Address	5005 SOUTH 40TH STREET SUITE 1200 PHOENIX, AZ 85040
Ethnicity	BMI	Report Date/Time 11/22/2017, 08:40 AM			

INFLAMMATION							Previous Result	Date
	In Range	Out of Range	Flag**	Relative Risk	Reference Range	Units		
Lp-PLA ₂ Activity ⁽¹⁾	60			LOW	<75	nmol/ min/mL		
Based on the documented clinical utility of Lp-PLA ₂ Activity to assess risk of CHD (1), the following cut-off has been defined for Lp-PLA ₂ Activity: A cut-off of ≥ 75 nmol/min/mL defines a population with increased relative risk of developing CHD. (Reference: 1-The Lp-PLA ₂ Studies Collaboration. Lancet. 2010; 375: 1536-1544).								

Comments

(1) This test is performed by a Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS) method. This test was developed and its performance characteristics determined by the Cleveland HeartLab, Inc. It has not been cleared or approved by the U.S. FDA. The Cleveland HeartLab is regulated under Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

**Flags: H = Out of Range High; L = Out of Range Low; CH = Critical High; CL = Critical Low